Abingdon Health PLC Exclusive Manufacturing Agreement with BioSure
July 23 2021 - 1:00AM
RNS Non-Regulatory
TIDMABDX
Abingdon Health PLC
23 July 2021
Exclusive Lateral Flow Manufacturing Agreement with BioSure UK
Limited
York, U.K. 23 July 2021: Abingdon Health plc (AIM: ABDX)
("Abingdon" or "the Company"), a leading international developer
and manufacturer of high quality and effective rapid tests, today
announces that it has signed an exclusive manufacturing agreement
with BioSure Limited ("BioSure"), a UK company specialising in the
provision of rapid in-vitro diagnostic testing solutions.
Under the terms of the exclusive agreement, Abingdon will
manufacture BioSure's own lateral flow tests in the field of
COVID19. The contract manufacturing services will utilise lateral
flow manufacturing facilities at Abingdon's York and Doncaster
sites.
Chris Yates, CEO of Abingdon Health, commented: " We are
delighted to be supporting BioSure and building on our long-term
collaboration with the BioSure team. We are committed to supporting
the deployment of these much needed lateral flow test to the UK and
international markets."
Brigette Bard, CEO of BioSURE, commented: "We are thrilled to be
continuing to build our portfolio of products with Abingdon.
BioSure is committed to delivering British developed tests to the
global market and Abingdon are our ideal partner to manufacture our
world-leading products."
Enquiries:
Abingdon Health plc
Chris Yates Chief Executive Officer Via Consilium
Dr Chris Hand Non-Executive Chairman
Melanie Ross Chief Financial Officer
Consilium Financial PR Tel: +44 (0) 7720 088 468
Matthew Neal abingdonhealth@consilium-comms.com
Mary-Jane Elliott
Davide Salvi
About Abingdon Health
Abingdon Health is a world leading developer and manufacturer of
high-quality rapid tests across all industry sectors, including
healthcare and COVID-19. Abingdon is the partner of choice for a
growing global customer base and takes projects from initial
concept through to routine and large-scale manufacturing and has
also developed and marketed its own labelled tests.
The Company offers product development, regulatory support,
technology transfer and manufacturing services for customers
looking to develop new assays or transfer existing laboratory-based
assays to a lateral flow format. Abingdon Health aims to support
the increase in need for rapid results across many industries and
locations and produces lateral flow tests in areas such as
infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access
to results allows for rapid decision making, targeted intervention
and can support better outcomes. This ability has a significant
role to play in improving life across the world. To support this
aim Abingdon Health has also developed AppDx(R), a customisable
image capturing technology that transforms a smartphone into a
self-sufficient, standalone lateral-flow reader.
Founded in 2008, Abingdon Health is headquartered in York,
England.
https://www.abingdonhealth.com/
About BioSure (UK) Limited
BioSure (UK) Limited are the manufacturers of the first CE
marked HIV Self-Test for personal use giving results in minutes.
Since launching in 2015, the BioSURE HIV Self Test has helped
people throughout the UK and the world, to #knowyourstatus. Since
the beginning of the COVID-19 pandemic, BioSure have pivoted their
expertise and now have a range of UK developed and manufactured
COVID-19 tests, which are available for professional use in the UK
and international markets.
Since launching the world's first approved blood-based HIV
self-test, BioSure has worked with governments, communities, and
individuals across the world, generating conversations, giving
people a choice of being able to test themselves and know their own
status on their own terms and just as importantly, giving people
the confidence to make informed choices.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAZLLFLFDLLBBE
(END) Dow Jones Newswires
July 23, 2021 02:00 ET (06:00 GMT)
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Apr 2023 to Apr 2024